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Abstract
Background—Women with chronic diseases are at increased risk of having unintended 
pregnancies. Little is known whether chronic diseases are associated with increased likelihood of 
effective/highly effective contraceptive use.
Methods—We analyzed 2008–2010 Florida Behavioral Risk Factor Surveillance System data for 
women aged 18–44 years who were at risk of unintended pregnancy. Multivariable Poisson 
regression estimated adjusted prevalence ratios (aPRs) and 95% confidence intervals (CIs) for 
contraceptive use in relation to diabetes, cardiovascular disease (CVD), and current asthma. We 
assessed the association of chronic disease status with use of three different contraception 
outcomes: (1) any method versus none, (2) less effective methods (methods associated with ≥10 
unintended pregnancies/100 women/year) versus none, and (3) effective/highly effective methods 
(<10 unintended pregnancies/100 women/year) versus none.
Results—Among 4473 women at risk for unintended pregnancy, 87% were using any method of 
contraception (22.5% less effective methods and 64.5% effective/highly effective methods). 
Women with CVD were more likely than those without CVD to use any contraception (aPR = 
1.09, 95% CI: 1.04, 1.15), less effective (aPR = 1.39, 95% CI: 1.13, 1.70), and effective/highly 
effective (aPR = 1.10, 95% CI: 1.03, 1.19) contraception. Women with diabetes were more likely 
to use less effective methods than women without diabetes (aPR = 1.34, 95% CI: 1.05, 1.72). No 
significant associations were observed for asthma, regardless of contraceptive effectiveness.
Conclusions—Self-reported use of effective/highly effective contraception was higher than 
nonuse or use of less effective methods among all women at risk of unintended pregnancy, but 
could be improved, especially among women with chronic diseases.
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Diabetes, hypertension, and asthma have been increasing among reproductive-age women1 
and are risk factors for adverse perinatal outcomes, including spontaneous abortions, 
congenital malformations, preterm birth, infants who are large for gestational age, fetal 
growth restriction, low birth weight, cesarean section, superimposed preeclampsia, renal 
deterioration, and in severe acute cases, maternal and fetal death.2–14 In addition, women 
with chronic diseases are more likely to report that their pregnancies are unintended 
compared to women without chronic diseases.15 Unintended pregnancies carry their own 
increased risks for preterm delivery and premature rupture of membranes compared to 
intended pregnancies.16
Federal and state committees have recommended that health care professionals provide 
preconception counseling and appropriate family planning or contraception services to 
women, especially women with chronic diseases, to optimally time pregnancy and minimize 
morbidity and mortality.17,18 Few studies have examined the relation between prepregnancy 
chronic disease status and contraceptive use.15,19–22 Of these, two have shown some 
associations between chronic disease and contraceptive use with results varying depending 
on the chronic disease examined.20,22 No published studies have examined associations 
between chronic disease and contraceptive use by effectiveness of contraception.
We examined survey data from the general population of women (age 18–44 years) at risk of 
having an unintended pregnancy in Florida. Our objective was to assess whether three 
common chronic diseases (diabetes, cardiovascular disease [CVD], or asthma) were 
associated with use of contraception, according to various levels of effectiveness. We also 
assessed potential effect modification by age group and conducted exploratory descriptive 
analyses to examine the prevalence of specific contraceptive methods by chronic disease 
status and age group.
Materials and Methods
Data source
Data from the 2008 to 2010 Florida Behavioral Risk Factor Surveillance System (BRFSS) 
were used for this study. BRFSS is a large ongoing random-digit-dialed telephone survey 
with a cross-sectional sample, administered annually to U.S. civilians at least 18 years of age 
living in households. Survey response rates in Florida ranged from 45.5% to 50.4% in 2008–
2010. In 2011, BRFSS implemented new sampling and weighting methodologies by 
including cellular telephone respondents as opposed to landline respondents only and 
applying a more sophisticated “raking” (i.e., an iterative proportional fitting) method as 
opposed to the standard “post-stratification” method to weight the data. Furthermore, the 
Florida survey included detailed questions on contraceptive use in 2011 and not in 
subsequent years, impeding our ability to conduct robust analyses. Consequently, survey 
data from 2011 onward were not included in this study. Details on BRFSS methodology are 
available elsewhere.23 Our study was granted exempt status by the Institutional Review 
Board at the Florida Department of Health.
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For the outcome, contraceptive use, participants were asked “Are you or your husband/
partner doing anything now to keep you from getting pregnant?” Those who responded 
“Yes” were then asked, “What are you or your husband/partner doing now to keep you from 
getting pregnant?” We categorized contraceptives as no method (referent), less effective, or 
effective/highly effective to examine whether women with chronic diseases were more likely 
to use effective/highly effective methods.24 Less effective methods were defined as those 
associated with 10 or more unintended pregnancies per 100 women per year during typical 
use (diaphragms, male and female condoms, withdrawal, sponge, cervical cap, spermicide, 
and fertility-awareness methods). Effective/highly effective methods were defined as those 
associated with less than 10 unintended pregnancies per 100 women per year during typical 
use (male and female sterilization, intrauterine devices [IUDs], implants, injections, oral 
contraceptive pills, vaginal rings, and the patch). The category no method was assigned if 
the participant or her husband/partner were not doing anything now to keep from getting 
pregnant. We also examined use of any contraception (yes, no).
We assessed three common and self-reported chronic diseases (diabetes, CVD, and asthma) 
among women of reproductive age that could be readily examined using BRFSS data. 
Hypertension, a major risk factor for CVD, was not assessed on the 2008 FL BRFSS survey 
and the data remaining in the other two survey years were too sparse to produce reliable 
estimates. Consequently, hypertension was not included in this study. For each condition, 
participants were asked whether they were told by a doctor, nurse or other health 
professional that they ever had the condition. Response options for diabetes, CVD, and 
asthma were “Yes,” “No,” “Not sure,” or “Refused.” Diabetes had two additional options: 
“Yes, but told only during pregnancy” and “No, pre-diabetes or borderline diabetes.” We 
categorized these women (n = 176) as not having diabetes, leaving 142 women with self-
reported diabetes. Women with CVD consisted of those who reported they ever had a heart 
attack, angina or coronary heart disease, or stroke (n = 100). Women were classified as 
having current asthma if they reported having asthma at the time of interview (n = 440). 
These three chronic conditions were also used to create a variable “any chronic disease” 
where existence of at least one of the three chronic conditions was identified. The potential 
confounders considered were identified a priori from those in the literature that are related to 
contraceptive use and to chronic disease, namely age (18–24, 25–34, 35–44 years), 
education (<high school degree, high school diploma, >high school diploma), race/ethnicity 
(non-Hispanic white, non-Hispanic black, Hispanic, non-Hispanic other), marital status 
(married, widowed/divorced/separated, never married/a member of an unmarried couple), 
body mass index (underweight/normal weight [<25.0 kg/m2], overweight [25.0–29.9 kg/m2], 
obese [≥30.0 kg/m2]), has health coverage (yes, no), and has a personal doctor (yes, no).
Exclusion criteria
Our sample population included 7368 women in Florida aged 18–44 years who responded to 
the 2008–2010 BRFSS surveys. We excluded 1835 women who were not at risk of having 
an unintended pregnancy, defined as pregnant women or women who were trying to get 
pregnant, were not sexually active, indicated not having a male partner, and reported having 
had a hysterectomy. Of the remaining 5533, women were also excluded if their contraceptive 
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use could not be determined (n = 656) and if data on diabetes, CVD, or asthma (n = 51) or 
potential confounders (n = 353) were missing, leaving 4473 women in the entire analytic 
sample. Given recommendations to exclude male partner or female sterilizations from 
assessments identifying women who risk unintended pregnancy as these methods have low 
contraceptive failure rates,25 we conducted sensitivity analyses where we excluded 
participants who reported male partner or female sterilization as their method of 
contraception (n = 1710).
Statistical analysis
All estimates were weighted using STATA v.12.1 to adjust for the survey design, stratified 
sampling, coverage, and response rates to produce accurate state-level estimates. We used 
chi-square analyses to test distribution differences of characteristics. Poisson regression with 
robust error variance was used to estimate unadjusted and adjusted prevalence ratios (aPRs) 
with 95% confidence intervals (CIs) for contraceptive use in relation to any and specific 
chronic diseases. In regression models for contraceptive effectiveness, women who were 
using less effective methods and women who were using effective/highly effective methods 
were analyzed separately and were individually compared to those who were using no 
method. Analyses were repeated for the sensitivity analysis. Poisson regression was more 
suitable for analyzing our highly prevalent outcomes than ordinary or multinomial (i.e., 
where less effective methods and effective/highly effective methods were compared, 
separately, to no method) logistic regression, which overestimated the observed prevalence 
ratios. Wald tests were used to examine potential effect modification by age. Lastly, to 
provide additional details of method use across any chronic disease status and age groups, 
individual methods were grouped into the following five categories: male and female 
sterilization, long-acting reversible contraceptive methods (LARCs; IUDs or implants), 
barrier methods (condoms, diaphragms, cervical caps, or sponges), short-acting reversible 
contraceptive methods (pills, injections, rings, or patches), and other (withdrawal, foams, 
jellies, creams, “unspecified other methods,” or emergency contraception). For this 
exploratory analysis, we were only able to present descriptive statistics because of the small 
sample sizes.
Results
Of 4473 women considered at risk for unintended pregnancy, 87% reported using 
contraception, with 64.5% using an effective/highly effective method and 22.5% using a less 
effective method (Table 1). The prevalence of effective/highly effective contraceptive use 
was lowest among women 18–24 years of age and those who were non-Hispanic other, 
unmarried, had no health insurance plan, and had no personal doctor. The overall weighted 
prevalence was 11.2% for any chronic disease, 2.7% for diabetes, 2.1% for CVD, and 7.7% 
for current asthma in our sample.
Relative to women without CVD, women with CVD were more likely to use any 
contraception (aPR = 1.09, 95% CI: 1.04, 1.15), less effective (aPR = 1.39, 95% CI: 1.13, 
1.70), and effective/highly effective (aPR = 1.10, 95% CI: 1.03, 1.19) methods of 
contraception (Table 2). Women with diabetes were more likely to use less effective methods 
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than women without diabetes (aPR = 1.34, 95% CI: 1.05, 1.72). Overall, the crude 
prevalence ratios and confidence intervals were comparable to the adjusted results. We 
observed no effect modification by age (data not shown, p = 0.07).
For the sensitivity analysis, the effect estimates before and after the exclusion of 
sterilizations were comparable with one exception: after adjustment, the association between 
effective/highly effective methods and CVD was no longer statistically significant (aPR= 
1.20, 95% CI: 0.95, 1.51).
After grouping individual methods into specific categories, male and female sterilizations 
were the most prevalent category of methods used among women 18 to 44 years of age 
(32.3%) while long-acting reversible contraceptive methods were the least prevalent (6.7%) 
(Table 3). Women <35 years of age with or without chronic disease tended to use short-
acting contraceptive methods more than older women (≥35 years) (p < 0.01). The prevalence 
of sterilization was significantly higher among women <35 years of age with chronic 
diseases (27.4% [95% CI: 18.8%, 38.0%]) than among women <35 years of age without 
chronic diseases (16.2% [95% CI: 13.0%, 19.9%]) (p = 0.02) (data not shown). Associations 
between individual method use and chronic disease (any or specific) could not be inferred 
with certainty because of small cell sizes.
Discussion
In our study, women with CVD were significantly more likely to use any, less effective, and 
effective/highly effective contraception than women without CVD; however, the association 
was strongest for use of less effective methods. Women with diabetes were significantly 
more likely to use less effective contraception compared to those without. The lack of 
association for women with any chronic diseases may have been driven by the substantially 
larger proportion of these women having asthma, which was not associated with 
contraceptive use. When examining the use of categories of individual contraceptive 
methods, we found one notable significant difference among women <35 years of age: the 
prevalence of sterilization was greater among women with chronic disease than among 
women without chronic disease.
Findings from our adjusted analyses on use of any contraception are consistent with results 
from some studies15,19,21 but not others.20,22 Unlike our study, Perritt et al.20 found no 
association between heart disease and any contraception use in a representative Maryland 
sample of recent mothers. They also reported lower odds of contraception use at conception 
among women with prepregnancy hypertension compared with non-hypertensive women 
(odds ratio [OR] = 0.5; 95% CI: 0.3, 0.8) and lower odds for postpartum contraception use 
among women with prepregnancy diabetes compared to women without (OR = 0.5; 95% CI: 
0.1, 0.9). We examined data among all women at risk of unintended pregnancy in the general 
population and not only among recent mothers. In another study that examined eight chronic 
medical conditions,22 women with at least one chronic condition were less likely to receive 
prescription contraception than women who had no chronic condition (OR = 0.85; 95% CI: 
0.76, 0.96). Notably, effect estimates for asthma and diabetes were comparable to ours and 
CVD was not assessed.
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Strengths of our study include using surveillance data of the general population of women at 
risk of unintended pregnancy, assessing multiple chronic diseases separately, and 
differentiating associations with contraceptive methods by level of effectiveness. One 
limitation is our use of self-reported survey data, which may have introduced potential 
misclassification of exposure and outcome variables as well as response and selection bias. 
There could be unmeasured confounding on variables that were not assessed on the survey 
such as parity. The 2008–2010 surveys had low response rates. Survey participants were a 
little older and had a higher percentage of non-Hispanic white women than the general 
Florida population.26 However, these differences were slight, and therefore potential 
selection bias should be minimal if the reason for non-inclusion was related to both the 
exposure and outcome. Our findings, which were based on Florida data, may not be 
generalizable to national or other state-level data. Furthermore, we were unable to examine 
reasons for nonuse or use of less effective methods, other chronic conditions such as 
hypertension, duration of chronic disease experience, types of hormone-based contraception 
(e.g., progestin-only versus combined oral contraceptive pills), respondents’ perceived risk 
of harm from use of hormone-based contraception, or the simultaneous use of multiple 
methods of contraception, because of the structure of the available dataset. Lastly, analyses 
based on small sample sizes may have had limited power to detect some associations.
Although the American College of Obstetricians and Gynecologists and the Centers for 
Disease Control and Prevention stress the importance of optimal preconception health for 
women with chronic disorders and provide guidelines to help clinicians select safe and 
effective methods of contraception for women with medical conditions, some clinicians do 
not provide contraceptive counseling.20 Medical providers may be unaware that they can 
safely prescribe some methods for women with chronic diseases, particularly hormonal 
contraceptive methods.20,27 Likewise, women with some chronic conditions may not know 
hormonal methods are viable options and therefore do not discuss the possibility with their 
providers. According to the U.S. Medical Eligibility Criteria (MEC),28 a tool that health care 
providers can use to determine the best method of contraception, women with CVD and 
diabetes can use effective/highly effective contraceptive methods safely, and the advantages 
of contraception for these women generally outweigh any theoretical risks. For example, 
barring severe, uncontrolled diabetes and other vascular disease that can be associated with 
diabetes, most women with diabetes can use combined hormonal methods, injections, 
implants, and IUDs. Effective/highly effective methods that are generally safe for women 
with CVD include progestin-only pills, implants, and IUDs. Although recommendations for 
asthma are not included in the 2010 U.S. MEC, women with asthma, particularly those with 
uncontrolled asthma, are at risk of adverse pregnancy-related outcomes, and therefore, 
unintended pregnancies should be reduced in this group as well.3,7,12
Conclusions
Although the prevalence of effective/highly effective contraception use was higher than that 
for use of less effective methods and nonuse among all women at risk of unintended 
pregnancy, our findings show room for improvement and support recommendations for 
preconception counseling about safe and effective/highly effective contraception tailored to 
women with chronic diseases who are at risk of unintended pregnancies. In addition, these 
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women may need more frequent and active follow-up in clinical settings to assure 
satisfaction with their contraceptive method. Given that LARCs were the least prevalent 
method used and that the prevalence of sterilization was significantly higher among younger 
women with chronic diseases than those without, research to better understand barriers to 
using reversible effective/highly effective contraception is needed among all women, 
especially those with chronic diseases.
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Table 1
Descriptive Estimates of Contraceptive Use by Characteristics of Women at Risk of Unintended Pregnancies
Characteristics No use, n (%) Less effective, n (%)a Effective/Highly effective, n (%)b pc
Overall 516 (13.0) 853 (22.5) 3104 (64.5)
Age, years
  18–24 58 (19.3) 136 (29.5) 261 (51.2)
  25–34 170 (12.9) 337 (25.0) 1125 (62.2)
  35–44 288 (11.5) 380 (18.9) 1718 (69.7) <0.01
Education
  <High school diploma 62 (14.4) 83 (33.4) 252 (52.2)
  High school diploma 143 (14.8) 222 (19.4) 830 (65.8)
  >High school diploma 311 (12.3) 548 (22.4) 2022 (65.3) 0.10
Race/ethnicity
  Non-Hispanic white 344 (11.6) 559 (19.8) 2340 (68.6)
  Non-Hispanic black 71 (16.8) 134 (27.6) 304 (55.7)
  Hispanic 74 (12.1) 121 (24.5) 354 (63.5)
  Non-Hispanic other 27 (21.0) 39 (29.5) 106 (49.5) 0.02
Marital status
  Married 307 (11.7) 449 (19.3) 2062 (69.0)
  Widowed, divorced, separated 71 (8.9) 132 (24.8) 459 (66.4)
  Unmarried, unmarried couple 138 (18.2) 272 (29.3) 583 (52.5) <0.01
Body mass index
  Not overweight or obese 215 (12.1) 399 (21.7) 1425 (66.2)
  Overweight 136 (12.6) 228 (22.6) 853 (64.8)
  Obese 165 (15.8) 226 (24.3) 826 (59.9) 0.49
Has any health insurance plan
  Yes 355 (12.2) 586 (21.4) 2459 (66.4)
  No 161 (16.2) 267 (26.4) 645 (57.4) 0.03
Has a personal doctor
  Yes 353 (11.0) 595 (22.9) 2414 (66.2)
  No 163 (18.4) 258 (21.6) 690 (60.0) <0.01
Any chronic diseased
  Yes 84 (14.4) 111 (23.5) 422 (62.1)
  No 432 (12.9) 742 (22.4) 2682 (64.8) 0.81
Diabetes
  Yes 21 (10.2) 29 (41.5) 92 (48.3)
  No 495 (13.1) 824 (22.0) 3012 (64.9) 0.05
Cardiovascular disease
  Yes 9 (3.4) 16 (33.7) 75 (62.9)
  No 507 (13.2) 837 (22.3) 3029 (64.5) 0.27
Current asthma
  Yes 60 (16.8) 81 (21.5) 299 (61.8)
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Characteristics No use, n (%) Less effective, n (%)a Effective/Highly effective, n (%)b pc
  No 456 (12.7) 772 (22.6) 2805 (64.7) 0.48
Unweighted frequencies and weighted row percentages are presented. Percentages may not total 100% due to rounding.
a
Less effective methods were defined as those associated with ≥10 unintended pregnancies per 100 women each year (i.e., condoms, diaphragm, 
withdrawal, sponges, cervical caps, spermicides, rhythm) with typical use.
b
Effective/highly effective methods were defined as those associated with <10 unintended pregnancies per 100 women each year (i.e., female and 
male sterilization, pills, intrauterine devices, implants, shots, vaginal ring, patch) with typical use.
c
χ2 p-values are for comparisons between characteristics and type of contraceptive use.
d
Includes diabetes, cardiovascular disease (heart attack, angina, coronary heart disease, or stroke), and current asthma.
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